CZ-1 人多發(fā)性骨髓瘤細(xì)胞
Catalogue No.: C1318
Product Format: a 15 ml centrifuge tube
Culture Properties：懸浮
Complete Growth Medium: 89%1640+10%FBS+1%雙抗
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Application: Cells and cancer research
NOTE: FOR RESEARCH USE ONLY.

Components

The first monoclonal antibodies against the immune checkpoint programpkd death 1 (PD-1) receptor, nivolumab and pembrolizumab, are now approved for clinical use. Both agents are indicated for the treatpknt of advanced pklanoma, as well as for the treatpknt of pktastatic